Related Experiment Videos
[Statins do not prevent restenosis after coronary angioplasty: where to go from here?]
M Horlitz1, U Sigwart, J Niebauer
1Medizinische Klinik 3, Kardiologie, Herzzentrum Wuppertal, Universität Witten/Herdecke. mhorlitz@hotmail.com
Background:
Despite the use of intracoronary stents, approximately 15-20% of patients who undergo percutaneous transluminal coronary angioplasty (PTCA) experience symptomatic restenosis. Known mechanisms of restenotic lesion formation are smooth muscle cell proliferation, extracellular matrix production, remodeling and decreased programmed cell death (apoptosis).
Results And Studies:
Experimental observations suggest that HMG-CoA reductase inhibitors ("statins") reduce the risk of restenosis. The activity of statins limits the rate of synthesis, not only of cholesterol, but also of a range of other molecules involved in cellular function. Their benefits in primary and secondary prevention of atherosclerosis have been widely recognized. Clinical trials using different types of statins were designed to evaluate their ability to influence the incidence of restenosis after successful conventional PTCA. The results clearly demonstrated that statins reduce lipid levels but do not prevent restenosis. Experimental evidence has failed to translate into clinical effect. The underlying pathological reasons for this shortcoming as well as promising alternative approaches including vascular gene therapy and brachytherapy will be discussed in this review.
Insights
Statins, used to lower cholesterol, do not prevent restenosis after coronary angioplasty. This review explores why experimental findings differ from clinical results and discusses alternative treatments for restenosis.
Area of Science:
- Cardiovascular Research
- Interventional Cardiology
- Molecular Medicine
Background:
- Percutaneous transluminal coronary angioplasty (PTCA) with stenting has a 15-20% restenosis rate.
- Restenosis involves smooth muscle cell proliferation, extracellular matrix production, remodeling, and reduced apoptosis.
- Statins are known for their cholesterol-lowering and anti-atherosclerosis effects.
Purpose of the Study:
- To evaluate the efficacy of statins in preventing restenosis post-PTCA.
- To explore the discrepancy between experimental observations and clinical trial outcomes regarding statins and restenosis.
- To discuss alternative therapeutic strategies for restenosis.
Main Methods:
- Review of experimental data and clinical trials on statin use for restenosis prevention.
- Analysis of the molecular mechanisms of statin action and restenosis.
- Discussion of emerging treatments like vascular gene therapy and brachytherapy.
Main Results:
- Clinical trials confirmed statins effectively reduce lipid levels.
- Statins did not demonstrate a significant effect in preventing restenosis after PTCA.
- A gap exists between preclinical evidence suggesting restenosis reduction and clinical ineffectiveness.
Conclusions:
- Statins' benefits in atherosclerosis do not translate to preventing restenosis.
- The underlying reasons for statin failure in restenosis prevention require further investigation.
- Vascular gene therapy and brachytherapy represent promising future avenues for managing restenosis.